169 related articles for article (PubMed ID: 23200931)
1. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
Yarlas A; Miller K; Wen W; Dain B; Lynch SY; Pergolizzi JV; Raffa RB; Ripa SR
J Pain; 2013 Jan; 14(1):14-23. PubMed ID: 23200931
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Brennan MJ; Ripa SR
Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
Yarlas A; Miller K; Wen W; Lynch SY; Ripa SR; Pergolizzi JV; Raffa RB
Pain Pract; 2016 Mar; 16(3):345-58. PubMed ID: 25599968
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Steiner D; Munera C; Hale M; Ripa S; Landau C
J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Pergolizzi JV; Raffa R; Ripa SR
Postgrad Med; 2015 Jan; 127(1):38-45. PubMed ID: 25526229
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
8. The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health.
Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Ripa SR; Pergolizzi JV; Raffa R
Clin J Pain; 2014 Dec; 30(12):1015-22. PubMed ID: 24394747
[TBL] [Abstract][Full Text] [Related]
9. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
10. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Dain B; Pergolizzi JV; Raffa R; Ripa SR
Pain Pract; 2016 Apr; 16(4):473-85. PubMed ID: 25865734
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.
Gordon A; Rashiq S; Moulin DE; Clark AJ; Beaulieu AD; Eisenhoffer J; Piraino PS; Quigley P; Harsanyi Z; Darke AC
Pain Res Manag; 2010; 15(3):169-78. PubMed ID: 20577660
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.
Rauck RL; Potts J; Xiang Q; Tzanis E; Finn A
Postgrad Med; 2016 Jan; 128(1):1-11. PubMed ID: 26634956
[TBL] [Abstract][Full Text] [Related]
13. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system.
Kosinski MR; Schein JR; Vallow SM; Ascher S; Harte C; Shikiar R; Frank L; Margolis MK; Vorsanger G
Curr Med Res Opin; 2005 Jun; 21(6):849-62. PubMed ID: 15969885
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study.
Leng X; Li Z; Lv H; Zheng Y; Liu Y; Dai K; Yao C; Yan X; Zeng X
Clin J Pain; 2015 Jul; 31(7):612-20. PubMed ID: 25503600
[TBL] [Abstract][Full Text] [Related]
18. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
Weil AJ; Masters ET; Barsdorf AI; Bass A; Pixton G; Wilson JG; Wolfram G
Health Qual Life Outcomes; 2017 Oct; 15(1):202. PubMed ID: 29041942
[TBL] [Abstract][Full Text] [Related]
20. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
Ripa SR; McCarberg BH; Munera C; Wen W; Landau CJ
Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
